Immune begins Phase I/II of Ceplene in CMML

Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) began a Phase I/II trial to evaluate twice-daily 0.5 mg subcutaneous Ceplene histamine dihydrochloride

Read the full 197 word article

How to gain access

Continue reading with a
two-week free trial.